… meta-analysis is to evaluate the efficacy of molnupiravir among mild or moderate COVID-19 patients. This meta-analysis … Items for Systematic Reviews and Meta-Analyses. Two authors …
JJ Malin, S Weibel, H Gruell… - Journal of …, 2023 - academic.oup.com
… Our analysis does not support routine use of molnupiravir for COVID-19 treatment in … We found that early treatment with molnupiravir probably does not reduce the combined outcome ‘…
C Huang, TL Lu, L Lin - Antibiotics, 2023 - mdpi.com
… Regarding the hospitalization rate, two studies reported the hospitalization rate in the current meta-analysis and demonstrated that molnupiravir was associated with a similar …
M Sun, H Lai, J Huang, J Liu, Y Li, J Tian… - Journal of …, 2023 - academic.oup.com
… efficacy and safety of molnupiravir need reassessment. Therefore, … molnupiravir for the treatment of non-severe (mild or moderate) COVID-19, and conduct subgroup analyses and meta-…
F Tian, Q Feng, Z Chen - International Journal of Antimicrobial Agents, 2023 - Elsevier
… There are currently some differences in the research results of molnupiravir. This study aimed to evaluate the efficacy and safety of molnupiravir in the treatment of COVID-19. …
Y Gao, M Liu, Z Li, J Xu, J Zhang, J Tian - Clinical Microbiology and …, 2023 - Elsevier
… of molnupiravir in treating patients with mild-to-moderate COVID-19. Our findings reveal that molnupiravir … and patients can consider molnupiravir as an option for the treatment of mild or …
… This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with molnupiravir in the treatment of coronavirus disease 2019 (COVID-19). To end this, PubMed, …
M Sun, H Lai, Z Zhang, L Ge - Journal of Antimicrobial …, 2023 - academic.oup.com
… mortality with molnupiravirtreatment.We share your concerns about the efficacy of molnupiravir, … In addition, there have been multiple studies showing that molnupiravir may cause new …
T Pitre, R Van Alstine, G Chick, G Leung, D Mikhail… - Cmaj, 2022 - Can Med Assoc
… This study is to evaluate benefit of adding Molnupiravir over standard treatments in mild COVID-19 subjects. Cochrane Central Register of Controlled Trials: CTRI/2021/06/033938. …